ABSTRACT
Melinda Cooper examines the contemporary Chinese hospital system, which is caught between the conflicting tasks of delivering basic health care within operating budgets, and acting as a clinical research site for foreign and domestic drug developers. Through analysis of recent rounds of healthcare reform, Cooper shows how governing authorities have sought to leverage existing scientific expertise and a huge patient base in an attempt to turn the hospital system into a source of indigenous biomedical experimentation and innovation.
